Potent dual ErbB-2/EGFR tyrosine kinase inhibitor. IC50= 0.01 and 0.014 µM for EGFR and ErbB-2. Orally active.
Features and Benefits
This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Sold for research purposes under agreement from GlaxoSmithKline
This product has met the following criteria: